
1. Technology overview
OxyPrem AG is a Swiss company with registered office at the neonatology clinic of the University of Zurich and an office in Schlieren, Switzerland. It makes non-invasive sensors that give real-time insight into tissue oxygen levels in newborns.
NOAH is a tissue oximetry system for routine continuous monitoring in critical care. Its sensor is non-adhesive and reusable and designed for the smallest patients, and it uses more than 10 wavelengths of light with a dynamic calibration approach to reduce surface signal contamination. The earlier OxyPrem 1.4 device is reported in use at hospitals in 13 countries. The homepage states that NOAH has obtained CE marking.
2. Highlighted features & specifications
- Reusable sensor: non-adhesive design for the smallest patients.
- Multi-wavelength sensing: more than 10 wavelengths of light.
- Dynamic calibration: reduces surface signal contamination.
- Continuous monitoring: real-time tissue oximetry for critical care.
- Phantom validation: liquid phantom method reproducible across neonatal oxygenation states.
- OxyPrem 1.4: self-calibrating sensor usable under a CPAP cap or with a bandage.
3. Potential application
Neonatal ICUs in Vietnamese obstetric and children's hospitals could monitor brain and tissue oxygenation in preterm infants. Research groups could use it in neonatal studies. Distributors of neonatal equipment could add it to their portfolios.
4. Benefits
Non-adhesive reusable sensor suits the smallest patients. Continuous real-time tissue oximetry supports routine critical care monitoring. Positioned as a cost-effective option for hospitals worldwide. In vivo precision of 1.85 percent or better is reported for the OxyPrem tissue oximeter.
5. Market trends & opportunities
Neonatal intensive care units increasingly look for non-invasive monitoring of tissue oxygenation to protect brain development in preterm infants. Vietnam's neonatal units in provincial and central hospitals are expanding capacity and could use cost-effective monitors.
6. Other information
OxyPrem AG, c/o University of Zurich Neonatology, Frauenklinikstrasse 10, 8091 Zurich; office in Schlieren (UID CHE-179.226.970). Fifth European patent granted in September 2026. The NOAH product page is marked coming soon while the homepage states CE marking was obtained.
One platform connecting startups, corporations, research institutions, regions and investors











Playbook & Handbook · February 6, 2026
Winning Accelerator Playbook 2026 by BambuUP
RETAIL E-COMMERCE: AI AND REAL-TIME DATA ARE TRANSFORMING HOW RETAIL BUSINESSES OPERATE








































